Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH ), a beta integrin antagonist, in patients with solid tumours

Cianfrocca, M E ; Kimmel, K A ; Gallo, J ; Cardoso, T ; Brown, M M ; Hudes, G ; Lewis, N ; Weiner, L ; Lam, G N ; Brown, S C ; Shaw, D E ; Mazar, A P ; Cohen, R B

British journal of cancer, 2006-06, Vol.94 (11), p.1621-1626 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível